Literature DB >> 6092562

Cyclic guanosine 3':5'-monophosphate mimics the effects of light on a circadian pacemaker in the eye of aplysia.

A Eskin, J S Takahashi, M Zatz, G D Block.   

Abstract

Environmental light regulates the phase of a circadian oscillator in the eye of Aplysia. We are attempting to define the events involved in transmitting light information from the environment to the circadian pacemaking mechanism in the eye. In this paper, we present several lines of evidence that cyclic guanosine 3':5'-monophosphate (cGMP) is involved in the photic entrainment pathway. Light increases the level of cGMP in eyes without having detectable effects on cyclic adenosine 3':5'-monophosphate (cAMP). An analogue of cGMP, 8-bromoguanosine 3':5'-cyclic monophosphate (cGMP), can shift the phase of the circadian rhythm from the eye; the phase response curves for light and for 8-bromo cGMP are indistinguishable. Neither 8-bromo cAMP nor 8-bromo 5'-GMP mimics the effect of light or of 8-bromo cGMP on the rhythm. Light and 8-bromo cGMP appear to use convergent mechanisms for entrainment since the effects of these two treatments are nonadditive. Also, low Na+ solutions antagonize the effects of both treatments. Finally, the kinetics of phase shifting by 8-bromo cGMP are similar to the kinetics of phase shifting by light. In addition to perturbing the circadian rhythm, 8-bromo cGMP increases the frequency of spontaneous optic nerve impulses. The pattern of nerve impulses during 8-bromo cGMP treatment is the same as the pattern of impulses produced by light. The excitatory effect of 8-bromo cGMP, the low Na+ blockade of the effects of 8-bromo cGMP, and the involvement of membrane depolarization in phase shifting by light suggest that depolarization mediates the effect of 8-bromo cGMP on the rhythm.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092562      PMCID: PMC6564693     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  9 in total

1.  Biography of Joseph S. Takahashi.

Authors:  Melissa Marino
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

2.  Coupling of muscarinic cholinergic receptors and cGMP in nocturnal regulation of the suprachiasmatic circadian clock.

Authors:  C Liu; J M Ding; L E Faiman; M U Gillette
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

3.  cGMP induces phase shifts of a mammalian circadian pacemaker at night, in antiphase to cAMP effects.

Authors:  R A Prosser; A J McArthur; M U Gillette
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  The Bulla ocular circadian pacemaker. II. Chronic changes in membrane potential lengthen free running period.

Authors:  D G McMahon; G D Block
Journal:  J Comp Physiol A       Date:  1987-08       Impact factor: 1.836

5.  The Bulla ocular circadian pacemaker. I. Pacemaker neuron membrane potential controls phase through a calcium-dependent mechanism.

Authors:  D G McMahon; G D Block
Journal:  J Comp Physiol A       Date:  1987-08       Impact factor: 1.836

6.  On the role of Ca2(+)-calmodulin-dependent and cAMP-dependent protein phosphorylation in the circadian rhythm of Neurospora crassa.

Authors:  D Techel; G Gebauer; W Kohler; T Braumann; B Jastorff; L Rensing
Journal:  J Comp Physiol B       Date:  1990       Impact factor: 2.200

7.  Calcium plays a central role in phase shifting the ocular circadian pacemaker of Aplysia.

Authors:  C S Colwell; D Whitmore; S Michel; G D Block
Journal:  J Comp Physiol A       Date:  1994-10       Impact factor: 1.836

8.  Evidence that potassium channels mediate the effects of serotonin on the ocular circadian pacemaker of Aplysia.

Authors:  C S Colwell; S Michel; G D Block
Journal:  J Comp Physiol A       Date:  1992-12       Impact factor: 1.836

9.  cAMP-dependent signaling as a core component of the mammalian circadian pacemaker.

Authors:  John S O'Neill; Elizabeth S Maywood; Johanna E Chesham; Joseph S Takahashi; Michael H Hastings
Journal:  Science       Date:  2008-05-16       Impact factor: 47.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.